|  |  | 

India Top Headlines

‘A Tipping Point’, Says Prime Minister Modi, As Oxford, Bharat Biotech’s Covid-19 Vaccines Gain Restricted Emergency Use Approval | India News

img-responsive

NEW DELHI: Prime Minister Narendra Modi congratulated the nation on Sunday and thanked the scientific and the health community after the Comptroller General of Drugs of India (DCGI) gave final approval to Oxford-AstraZeneca’s Covishield and Bharat Biotech’s Covaxin vaccines for emergency use.
The announcement marks a “decisive turning point” in India’s fight against the Covid-19 pandemic, Prime Minister Modi tweeted shortly after the announcement. Prime Minister Modi said this will speed up the process for India to become a Covid-free nation. “All of India would be proud that both vaccines are” made in India, “Prime Minister Modi said.
The DCGI today approved the Oxford Covid-19 Covishield vaccine, manufactured by the Serum Institute, and locally developed Bharat Biotech’s Covaxin for restricted emergency use in the country, paving the way for a mass inoculation campaign. The DCGI approval was given based on the recommendations submitted by a COVID-19 subject matter expert committee (SEC) of the Central Drug Standards Control Organization (CDSCO).

“All Indians would be proud that the two vaccines that have received emergency use approval are made in India! This shows the enthusiasm of our scientific community to fulfill the dream of an Aatmanirbhar Bharat, at the root of which is care and compassion, ”said the prime minister.
The Serum Institute of India, the world’s largest vaccine manufacturer, has partnered with AstraZeneca to manufacture Covishield.
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR).



Times of India

a-tipping-point-says-prime-minister-modi-as-oxford-bharat-biotechs-covid-19-vaccines-gain-restricted-emergency-use-approval-india-news

ABOUT THE AUTHOR